Patents by Inventor Per J. Greisen

Per J. Greisen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
    Publication number: 20240067944
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Application
    Filed: July 7, 2023
    Publication date: February 29, 2024
    Applicant: Novo Nordisk A/S
    Inventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION
    Publication number: 20240043516
    Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
    Type: Application
    Filed: September 5, 2023
    Publication date: February 8, 2024
    Inventors: Anette Henriksen, Thomas Nylandsted Krogh, Per J. Greisen, Thomas Egebjerg
  • NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION
    Publication number: 20230348582
    Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
    Type: Application
    Filed: May 2, 2023
    Publication date: November 2, 2023
    Inventors: Anette Henriksen, Thomas Nylandsted Krogh, Per J. Greisen, Thomas Egebjerg
  • Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
    Patent number: 11780910
    Abstract: The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: October 10, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Anette Henriksen, Thomas Nylandsted Krogh, Per J. Greisen, Thomas Egebjerg
  • Procoagulant Antibodies
    Publication number: 20230058721
    Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.
    Type: Application
    Filed: November 10, 2021
    Publication date: February 23, 2023
    Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
  • Procoagulant antibodies
    Patent number: 11220554
    Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: January 11, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
  • Procoagulant Antibodies
    Publication number: 20210388114
    Abstract: The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.
    Type: Application
    Filed: February 1, 2018
    Publication date: December 16, 2021
    Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
  • PROCOAGULANT ANTIBODIES
    Publication number: 20210238306
    Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.
    Type: Application
    Filed: January 29, 2021
    Publication date: August 5, 2021
    Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou